Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.


Journal

Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386

Informations de publication

Date de publication:
01 2019
Historique:
received: 20 05 2018
revised: 16 07 2018
accepted: 25 07 2018
pubmed: 19 9 2018
medline: 23 2 2020
entrez: 19 9 2018
Statut: ppublish

Résumé

Waldenström's macroglobulinemia (WM) is a rare malignancy characterized by bone marrow infiltration by lymphoplasmacytic cells and the presence of a monoclonal IgM paraprotein. The interactions of lymphoplasmacytic cells with other cells in their microenvironment, including mast cells and endothelial cells, support their survival and proliferation and can induce resistance to therapy. von Willebrand factor (vWF) plays a key role in primary hemostasis but is also a marker of endothelial "stimulation." High levels of vWF have been associated with an adverse prognosis in patients with symptomatic WM and might reflect the interactions between lymphoplasmacytic cells and other cells of their microenvironment. Considering vWF and ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) as markers of endothelial dysfunction and activation, we evaluated the prognostic importance of vWF and ADAMTS-13 antigen levels in the serum of patients with previously untreated symptomatic WM to validate vWF as a possible prognostic marker for progression-free and overall survival. We also validated the measurement of vWF in the serum instead of citrated plasma and investigated the possible correlations of ADAMTS-13 antigen levels with disease characteristics. The analysis included 42 patients with symptomatic WM and 19 matched healthy controls. The serum levels of vWF antigen provided significant prognostic information, and patients with levels ≥ 200 IU/dL had a very poor prognosis compared with patients with lower levels. The ADAMTS-13 antigen levels were decreased in WM patients and correlated with the IgM levels, β vWF levels measured in the serum could become an important prognostic marker in patients with WM and requires further investigation.

Sections du résumé

BACKGROUND
Waldenström's macroglobulinemia (WM) is a rare malignancy characterized by bone marrow infiltration by lymphoplasmacytic cells and the presence of a monoclonal IgM paraprotein. The interactions of lymphoplasmacytic cells with other cells in their microenvironment, including mast cells and endothelial cells, support their survival and proliferation and can induce resistance to therapy. von Willebrand factor (vWF) plays a key role in primary hemostasis but is also a marker of endothelial "stimulation." High levels of vWF have been associated with an adverse prognosis in patients with symptomatic WM and might reflect the interactions between lymphoplasmacytic cells and other cells of their microenvironment.
MATERIALS AND METHODS
Considering vWF and ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) as markers of endothelial dysfunction and activation, we evaluated the prognostic importance of vWF and ADAMTS-13 antigen levels in the serum of patients with previously untreated symptomatic WM to validate vWF as a possible prognostic marker for progression-free and overall survival. We also validated the measurement of vWF in the serum instead of citrated plasma and investigated the possible correlations of ADAMTS-13 antigen levels with disease characteristics. The analysis included 42 patients with symptomatic WM and 19 matched healthy controls.
RESULTS
The serum levels of vWF antigen provided significant prognostic information, and patients with levels ≥ 200 IU/dL had a very poor prognosis compared with patients with lower levels. The ADAMTS-13 antigen levels were decreased in WM patients and correlated with the IgM levels, β
CONCLUSION
vWF levels measured in the serum could become an important prognostic marker in patients with WM and requires further investigation.

Identifiants

pubmed: 30224328
pii: S2152-2650(18)30532-9
doi: 10.1016/j.clml.2018.07.294
pii:
doi:

Substances chimiques

Immunoglobulin M 0
ADAMTS13 Protein EC 3.4.24.87
ADAMTS13 protein, human EC 3.4.24.87

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-28

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Maria Gavriatopoulou (M)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mariagabria@gmail.com.

Evangelos Terpos (E)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Ioannis Ntanasis-Stathopoulos (I)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Ioannis Papasotiriou (I)

Department of Clinical Biochemistry, Aghia Sophia Children's Hospital, Athens, Greece.

Despoina Fotiou (D)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Magdalini Migkou (M)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Maria Roussou (M)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Nikolaos Kanellias (N)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Dimitrios Ziogas (D)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Ioanna Dialoupi (I)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Evangelos Eleutherakis Papaiakovou (E)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Efstathios Kastritis (E)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Meletios Athanasios Dimopoulos (MA)

Department of Oncology, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH